The World Health Organization (WHO) has approved the MVA-BN vaccine, developed by Bavarian Nordic A/S, as the first mpox vaccine to be added to its prequalification list. This move is expected to improve access to the vaccine in regions with urgent outbreaks, particularly in Africa, helping to control the disease’s spread. WHO Director-General Tedros Adhanom Ghebreyesus highlighted the importance of scaling up vaccine distribution for those most at risk. The vaccine is given in two doses, four weeks apart, and has shown 76% effectiveness after one dose and 82% after two doses.
Source – CGTN
You can listen to the programs organized by MI Radio on Google Podcast, Apple Podcast and Spotify.
You can download MI Radio application on Google Play Store and Apple App Store.
